Effectiveness and safety of Sacituzumab Govitecan in Chinese patients with metastatic breast cancer
Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study
This study is testing how well and safely the drug Sacituzumab Govitecan works for people in China with metastatic breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | Sacituzumab |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06356519 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the real-world effectiveness and safety of Sacituzumab Govitecan in patients with metastatic breast cancer in China. It will assess potential predictors of treatment response among those who are receiving or have received this therapy. The study will involve collecting and analyzing medical histories and treatment outcomes from eligible participants to better understand the drug's impact in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with metastatic breast cancer who are planning to receive or have already received Sacituzumab Govitecan.
Not a fit: Patients with incomplete medical histories or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Sacituzumab Govitecan, potentially leading to improved treatment strategies for metastatic breast cancer patients.
How similar studies have performed: While this study focuses on a specific population and treatment, similar studies evaluating the effectiveness of Sacituzumab Govitecan have shown promising results in other settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Plan to receive or has received Sacituzumab Govitecan monotherapy 4. Available medical history. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or breast-breeding
Where this trial is running
Shanghai, Shanghai
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Biyun Wang, Professor — Fudan University
- Study coordinator: Biyun Wang, Professor
- Email: pro_wangbiyun@163.com
- Phone: +8613701748410
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.